huge volume entering anp, page-29

Personally I see several announcements to be made shortly.

1,
Financing of phase 2 trials for ATL1103 with acromegaly patients.
The financial side of things would have to be wrapped up at least 2 months prior to the start of the trials which we expect beginning in June.

2,
ATL1101 should get news within the next 2 to 3 months as contract with Afandin was extended for 6 months. This was a good development.
ISIS concentrates much of its programs on cancer research and ATL1101 prostate cancer drug would fit into the broader target zone of ISIS.
I therefore have little doubt that ATL1101 will be taken into clinical trials.


3,
We still miss market to appreciate the fact that ATL1102 is actively back to a play a role for ANP through the chinese contract.

4,
Stem cell mobilisation trials should be initiated within the same timeframe.



In that context, there are multiple announcements to be expected which could see the price quickly reach 5 to 6 cents in the next 3 months, I would say.